Revenio Group Oyj (REG1V.HE) | Investment Case

1. Company Snapshot

1.a. Company Description

Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally.The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities.

Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.

Show Full description

1.b. Last Insights on REG1V

Revenio Group Oyj faces margin compression, with its net profit margin decreasing to 16.9% from 19.2% previously. This decline is notable despite the company's solid earnings forecast, growing 17.4% per year, and revenue projected to increase 11.2% annually. The Finnish market's growth rates are lower, at 17.1% and 4.2% for earnings and revenue, respectively. Revenio's five-year earnings growth rate stands at 5.5%. Recent attention on the stock may be linked to its premium valuation versus growth outlook.

1.c. Company Highlights

Last Price	22.15
Change Percentage	1.61%
Open	21.75
Previous Close	21.8
Market Cap ( Millions)	589
Volume	23336
Year High	31.88
Year Low	21.35
M A 50	23.29
M A 200	25.31

FCF Yield	3.55%
Dividend Yield	1.81%
ROE	17.02%
Debt / Equity	4.60%
Net Debt / EBIDTA	-28.93%
Price To Book	5.67
Price Earnings Ratio	32.7
Price To FCF	28.19
Price To sales	5.51
EV / EBITDA	18.24

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Revenio Group (HLSE:REG1V) Margin Compression Sparks Debate on Premium Valuation Versus Growth Outlook

Oct -31

Source:

3 European Stocks That May Be Trading Below Intrinsic Value By Up To 37%

Oct -07

Source:

Does Heineken’s Slump Signal Opportunity After Record Low US Alcohol Consumption?

Sep -09

Source:

Enel (BIT:ENEL): Is the Current Valuation Overlooking Subtle Shifts in Performance?

Sep -09

Source:

Telecom Italia (BIT:TIT): Fresh Valuation Perspectives After Strong Share Price Momentum

Sep -09

Source:

Alfa Laval (OM:ALFA): Evaluating the Company’s Valuation as Investors Weigh Recent Modest Share Price Movements

Sep -09

Source:

Porsche SE (XTRA:PAH3): Assessing Value Potential Following Recent Share Price Stability

Sep -09

Source:

GL Events Valuation in Focus After Strong 61.7% Year-to-Date Rally

Sep -09

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.00%)

6. Segments

Ophthalmic Diagnostic Solutions

Expected Growth: 12%

Revenio Group Oyj's Ophthalmic Diagnostic Solutions segment growth is driven by increasing demand for early disease detection, advancements in optical coherence tomography (OCT) technology, and expanding presence in emerging markets. Additionally, growing prevalence of eye disorders, aging population, and rising healthcare expenditure contribute to the 12% growth.

7. Detailed Products

Revenio's Digital Health Solutions

Revenio's digital health solutions provide healthcare professionals with advanced tools to diagnose and monitor various eye conditions, including diabetic retinopathy and glaucoma.

Eye Clinic Management Software

Revenio's eye clinic management software streamlines clinical workflows, patient data management, and billing processes, improving efficiency and reducing costs.

Telemedicine Platforms

Revenio's telemedicine platforms enable remote consultations and monitoring, expanding access to eye care services, especially in underserved areas.

Artificial Intelligence (AI) and Machine Learning (ML) Solutions

Revenio's AI and ML solutions analyze medical images and data to aid in disease diagnosis, prediction, and prevention.

Medical Imaging and Diagnostics

Revenio's medical imaging and diagnostics solutions provide high-quality images and data analysis for accurate disease diagnosis and monitoring.

8. Revenio Group Oyj's Porter Forces

Forces Ranking

Threat Of Substitutes

Revenio Group Oyj operates in a niche market with limited substitutes, but there are some alternatives available to customers.

Bargaining Power Of Customers

Revenio Group Oyj has a diverse customer base, and no single customer has significant bargaining power.

Bargaining Power Of Suppliers

Revenio Group Oyj relies on a few key suppliers, but there are alternative suppliers available in the market.

Threat Of New Entrants

Revenio Group Oyj operates in a niche market with high barriers to entry, making it difficult for new entrants to join the market.

Intensity Of Rivalry

Revenio Group Oyj operates in a competitive market with several established players, leading to intense rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	13.54%
Debt Cost	5.43%
Equity Weight	86.46%
Equity Cost	10.42%
WACC	9.74%
Leverage	15.67%

11. Quality Control: Revenio Group Oyj passed 7 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Medistim

A-Score: 5.0/10

Value: 0.7

Growth: 6.2

Quality: 9.2

Yield: 3.8

Momentum: 8.0

Volatility: 2.0

1-Year Total Return ->

Revenio

A-Score: 4.1/10

Value: 1.1

Growth: 7.3

Quality: 8.4

Yield: 1.9

Momentum: 1.5

Volatility: 4.7

1-Year Total Return ->

Ion Beam Applications

A-Score: 3.7/10

Value: 6.3

Growth: 4.1

Quality: 4.1

Yield: 2.5

Momentum: 1.0

Volatility: 4.3

1-Year Total Return ->

CellaVision

A-Score: 3.5/10

Value: 1.3

Growth: 6.7

Quality: 8.0

Yield: 1.9

Momentum: 0.5

Volatility: 2.3

1-Year Total Return ->

Xvivo Perfusion

A-Score: 3.3/10

Value: 0.8

Growth: 9.8

Quality: 7.5

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

ReWalk Robotics

A-Score: 3.0/10

Value: 9.8

Growth: 4.0

Quality: 4.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

12.78%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

9.74%

Revenio Group Oyj - FI0009010912

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on REG1V

1.c. Company Highlights

Better Quality

Expensive

Stable Momentum

Earnings Miss

Revenues Beats

Average Growth

Higher Growth

Revenues Miss

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.00%)

6. Segments

Ophthalmic Diagnostic Solutions

Expected Growth: 12%

7. Detailed Products

Revenio's Digital Health Solutions

Eye Clinic Management Software

Telemedicine Platforms

Artificial Intelligence (AI) and Machine Learning (ML) Solutions

Medical Imaging and Diagnostics

8. Revenio Group Oyj's Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Revenio Group Oyj passed 7 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

22.15$

Current Price

22.15$

Potential

0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA